Incyte Analyst Ratings
Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Cuts Target Price to $81
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
GlaxoSmithKline Sell Rating Justified by Arexvy Underperformance and Reduced Revenue Projections
Analysts' Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $76
Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
GlaxoSmithKline (GSK) Receives a Buy From Jefferies
Gilead Sciences (GILD) Receives a Buy From TD Cowen
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
Berenberg Raises Price Target on Novartis to CHF86 From CHF77, Maintains Hold Rating
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Johnson & Johnson Analyst Ratings
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Gilead Sciences: A Balanced Outlook With Steady HIV Performance and Oncology Challenges Justifying a Hold Rating
Novartis AG (NOVN) Gets a Hold From Berenberg Bank